Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

In the DESTINY-Gastric01 phase II study (n=187), trastuzumab deruxtecan was associated with a higher objective response rate than chemotherapy (physician’s choice) in patients with HER2-positive advanced gastric cancer (51% v 14%; P<0.001).

SPS commentary:

Trastuzumab deruxtecan is an antibody-drug conjugate consisting of an anti-HER2 antibody (trastuzumab) and a cytotoxic topoisomerase I inhibitor, attached by a cleavable tetrapeptide-based linker. The results of this study are being presented at the ASCO Virtual Scientific Program.


New England Journal of Medicine